BR0317161A - Moléculas de ligação nogo a e uso farmacêutico das mesmas - Google Patents
Moléculas de ligação nogo a e uso farmacêutico das mesmasInfo
- Publication number
- BR0317161A BR0317161A BR0317161-2A BR0317161A BR0317161A BR 0317161 A BR0317161 A BR 0317161A BR 0317161 A BR0317161 A BR 0317161A BR 0317161 A BR0317161 A BR 0317161A
- Authority
- BR
- Brazil
- Prior art keywords
- human
- nogo
- binding molecule
- binding molecules
- pharmaceutical use
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
"MOLéCULAS DE LIGAçãO NOGO A E USO FARMACêUTICO DAS MESMAS". A presente invenção refere-se às moléculas, tais como, por exemplo, anticorpos monocionais ou fragmentos Fab das mesmas, que são capazes de ligação ao polipeptídeo NogoA humano ou NiG humano ou No-goA_623-640 humano com uma constante de dissociação < 1000nM; poli-nucleotídeos codificando tal molécula de ligação; um vetor de expressão compreendendo tais polinucleotídeos; o uso de tal molécula de ligação no tratamento de reparo do nervo; uma composição farmacêutica compreendendo tal molécula de ligação e a um processo de tratamento de doenças associadas ao reparo do nervo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0228832.2A GB0228832D0 (en) | 2002-12-10 | 2002-12-10 | Organic compound |
| PCT/EP2003/013960 WO2004052932A2 (en) | 2002-12-10 | 2003-12-09 | Antibody (“11c7”) anti nogo a and its pharmaceutical use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0317161A true BR0317161A (pt) | 2005-11-01 |
Family
ID=9949456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0317161-2A BR0317161A (pt) | 2002-12-10 | 2003-12-09 | Moléculas de ligação nogo a e uso farmacêutico das mesmas |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US7785593B2 (pt) |
| EP (1) | EP1572745B1 (pt) |
| JP (1) | JP4504200B2 (pt) |
| KR (1) | KR101215801B1 (pt) |
| CN (1) | CN100384877C (pt) |
| AT (1) | ATE475671T1 (pt) |
| AU (1) | AU2003289998B2 (pt) |
| BR (1) | BR0317161A (pt) |
| CA (1) | CA2509068C (pt) |
| CY (1) | CY1110848T1 (pt) |
| DE (1) | DE60333585D1 (pt) |
| DK (1) | DK1572745T3 (pt) |
| EC (1) | ECSP055849A (pt) |
| ES (1) | ES2349293T3 (pt) |
| GB (1) | GB0228832D0 (pt) |
| HK (1) | HK1084676A1 (pt) |
| IL (1) | IL169018A (pt) |
| MX (1) | MXPA05006265A (pt) |
| NO (1) | NO20053304L (pt) |
| PL (1) | PL210720B1 (pt) |
| PT (1) | PT1572745E (pt) |
| RU (1) | RU2350623C2 (pt) |
| SI (1) | SI1572745T1 (pt) |
| WO (1) | WO2004052932A2 (pt) |
| ZA (1) | ZA200504522B (pt) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0228832D0 (en) | 2002-12-10 | 2003-01-15 | Novartis Ag | Organic compound |
| GB0321997D0 (en) * | 2003-09-19 | 2003-10-22 | Novartis Ag | Organic compound |
| TWI329649B (en) * | 2003-12-22 | 2010-09-01 | Glaxo Group Ltd | Immunoglobulins |
| ES2391902T3 (es) * | 2005-07-05 | 2012-11-30 | Glaxo Group Limited | Anticuerpos humanizados específicos para NOGO-A y sus usos farmacéuticos |
| GB0525662D0 (en) | 2005-12-16 | 2006-01-25 | Glaxo Group Ltd | Immunoglobulins |
| DK2207808T3 (da) * | 2007-11-02 | 2013-08-05 | Novartis Ag | Forbedrede Nogo-A-bindingsmolekyler samt deres farmaceutiske anvendelse |
| CA2730473A1 (en) * | 2008-07-11 | 2010-01-14 | Glaxo Group Limited | Novel treatment |
| WO2012004773A1 (en) | 2010-07-09 | 2012-01-12 | Universite De Geneve | New uses of nogo-a inhibitors and related methods |
| WO2014006105A1 (en) | 2012-07-05 | 2014-01-09 | Glaxo Group Limited | Optimum dose regime of an anti-nogo-a antibody in the treatment of amyotrophic lateral sclerosis |
| US9534044B2 (en) * | 2013-02-28 | 2017-01-03 | United Arab Emirates University | Alpha-synuclein antibodies and uses thereof |
| EP3007556B1 (en) * | 2013-06-13 | 2020-05-20 | Biomatrica, INC. | Cell stabilization |
| MX2018010445A (es) | 2016-03-01 | 2019-10-17 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Anticuerpos especificos del receptor de poliovirus humano (rvp). |
| CN114599676A (zh) | 2019-10-24 | 2022-06-07 | 诺华康制药股份公司 | 新型抗-Nogo-A抗体 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308573D0 (en) | 1983-03-29 | 1983-05-05 | British Nuclear Fuels Ltd | Filament impregnating/coating |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| ATE87659T1 (de) | 1986-09-02 | 1993-04-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5180820A (en) | 1989-08-30 | 1993-01-19 | Barde Yves Alain | Brain-derived neurotrophic factor |
| ES2204890T3 (es) | 1991-03-06 | 2004-05-01 | Merck Patent Gmbh | Anticuerpos monoclonales humanizados. |
| JP2002522016A (ja) | 1998-07-22 | 2002-07-23 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 神経内分泌特異的タンパク質に類似したタンパク質、およびそれをコードするｃＤＮＡ |
| SK287323B6 (sk) | 1998-11-06 | 2010-07-07 | University Of Z�Rich | Nogo proteín, jeho purifikovaný fragment, chimérny proteín a purifikovaná molekula s jeho obsahom, izolovaná nukleová kyselina, vektor s jej obsahom, rekombinantná bunka, spôsob produkcie rekombinantného proteínu a jeho použitie |
| CU22921A1 (es) | 1999-11-16 | 2004-02-20 | Centro Inmunologia Molecular | Anticuerpos quimérico, humanizado y el fragmento de tipo fv de cadena sencilla que reconoce el antígeno c2. su uso en el diagnóstico y tratamiento de tumores colorrectales |
| EP2163561A1 (en) * | 2000-01-12 | 2010-03-17 | Yale University | NOGO receptor-mediated blockade of axonal growth |
| ES2437875T3 (es) * | 2001-04-30 | 2014-01-14 | Eli Lilly And Company | Anticuerpos humanizados que reconocen el péptido beta-amiloide |
| DE20110806U1 (de) | 2001-06-29 | 2001-12-20 | Jack Wolfskin Ausrüstung für Draussen GmbH, 65510 Idstein | Zelt |
| DK1461300T3 (da) * | 2001-11-30 | 2011-10-24 | Biogen Idec Inc | Antistoffer mod kemotaktiske monocytproteiner |
| GB0228832D0 (en) | 2002-12-10 | 2003-01-15 | Novartis Ag | Organic compound |
| TWI329649B (en) | 2003-12-22 | 2010-09-01 | Glaxo Group Ltd | Immunoglobulins |
| US7596225B2 (en) * | 2005-06-30 | 2009-09-29 | Alcatl-Lucent Usa Inc. | Method for refreshing a pairwise master key |
-
2002
- 2002-12-10 GB GBGB0228832.2A patent/GB0228832D0/en not_active Ceased
-
2003
- 2003-12-09 PL PL377506A patent/PL210720B1/pl unknown
- 2003-12-09 MX MXPA05006265A patent/MXPA05006265A/es active IP Right Grant
- 2003-12-09 CA CA2509068A patent/CA2509068C/en not_active Expired - Fee Related
- 2003-12-09 JP JP2004558049A patent/JP4504200B2/ja not_active Expired - Fee Related
- 2003-12-09 EP EP03782350A patent/EP1572745B1/en not_active Expired - Lifetime
- 2003-12-09 ES ES03782350T patent/ES2349293T3/es not_active Expired - Lifetime
- 2003-12-09 US US10/538,201 patent/US7785593B2/en not_active Expired - Fee Related
- 2003-12-09 CN CNB2003801096228A patent/CN100384877C/zh not_active Expired - Fee Related
- 2003-12-09 PT PT03782350T patent/PT1572745E/pt unknown
- 2003-12-09 AT AT03782350T patent/ATE475671T1/de active
- 2003-12-09 BR BR0317161-2A patent/BR0317161A/pt active Search and Examination
- 2003-12-09 DK DK03782350.7T patent/DK1572745T3/da active
- 2003-12-09 WO PCT/EP2003/013960 patent/WO2004052932A2/en active Application Filing
- 2003-12-09 DE DE60333585T patent/DE60333585D1/de not_active Expired - Lifetime
- 2003-12-09 RU RU2005121669/13A patent/RU2350623C2/ru not_active IP Right Cessation
- 2003-12-09 KR KR1020057010410A patent/KR101215801B1/ko not_active IP Right Cessation
- 2003-12-09 AU AU2003289998A patent/AU2003289998B2/en not_active Ceased
- 2003-12-09 SI SI200331887T patent/SI1572745T1/sl unknown
-
2005
- 2005-06-06 IL IL169018A patent/IL169018A/en not_active IP Right Cessation
- 2005-06-10 EC EC2005005849A patent/ECSP055849A/es unknown
- 2005-07-06 NO NO20053304A patent/NO20053304L/no not_active Application Discontinuation
-
2006
- 2006-02-08 ZA ZA200504522A patent/ZA200504522B/en unknown
- 2006-02-24 HK HK06102543.2A patent/HK1084676A1/xx not_active IP Right Cessation
-
2010
- 2010-06-18 US US12/819,060 patent/US8535666B2/en not_active Expired - Fee Related
- 2010-10-19 CY CY20101100934T patent/CY1110848T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1110848T1 (el) | Αντισωμα αντι ανθρωπου νοgo α kai h φαρμακευτικη του χρηση | |
| CY1117387T1 (el) | ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ | |
| CY1119197T1 (el) | Μεθοδος παροχης νοσο-ειδικων μοριων και στοχων δeσμευσης | |
| ECSP056263A (es) | Anticuerpos humanizados que reconocen el péptido beta amiloideo | |
| ATE416190T1 (de) | Polypeptide mit bindungsaffinität für her2 | |
| EA200901436A1 (ru) | Антигенсвязывающие белки, связывающие par-2 | |
| DE602005026219D1 (de) | Gegen das säugetier-eag1-ionenkanalprotein gerichtete antikörper | |
| WO2006083964A3 (en) | Modified fusion molecules for treatment of allergic disease | |
| WO2007039256A3 (de) | Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung | |
| NO20061678L (no) | NOGO-A bindingsmolekyler og funmsoytiske anvendelser derav | |
| ATE483806T1 (de) | Polynukleotide, welche für mitglieder der humanen b lymphozyten-aktivierendes antigen familie kodieren, und von diesen kodierte polypeptide | |
| DE69931482D1 (de) | Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen | |
| BRPI0407031A (pt) | Composições e métodos para tratamento de câncer empregando igsf9 e liv-1 | |
| DE60228504D1 (de) | P53 bindende t-zellrezeptormoleküle und deren verwendungen | |
| PE20090981A1 (es) | Moleculas aglutinantes de nogo-a mejoradas y uso farmaceutico de las mismas | |
| ATE312921T1 (de) | Antigene polypeptide aus neisseria meningitidis, dafür kodierende polynukleotide und entsprechende schützende antikörper | |
| SE0301987D0 (sv) | New polypeptide | |
| MXPA02005236A (es) | Metodos de tratamiento de lupus con base en la afinidad de anticuerpos y metodos de separacion por exclusion y composiciones para el uso de los mismos. | |
| BRPI0309730B8 (pt) | molécula de anticorpo possuindo especificidade para cd22 humana, sequência de dna, vetor de expressão ou clonagem, célula hospedeira, uso da molécula de anticorpo ou da sequência de dna, composição diagnóstica ou terapêutica, processo para a produção de uma molécula de anticorpo, processo para a preparação de uma composição diagnóstica ou terapêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 13A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] | ||
| B07F | Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette] |
Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229 DA LPI |